Information Provided By: 
Fly News Breaks for March 19, 2019
AGN, EOLS
Mar 19, 2019 | 16:46 EDT
SunTrust transferred coverage of Evolus (EOLS) to analyst Gregg Gilbert, who established a Buy rating and $29 price target on the stock. The analyst cites the company preparing to enter the US botulinum toxin market, adding that with Jeuveau "de-risked from a regulatory standpoint following FDA approval", investor focus will shift to the near-term launch of "frictionless alternative" to market-leading Botox from Allergan (AGN). Gilbert contends that Evolus could carve a "nice slice of this rapidly-growing market".
News For EOLS;AGN From the Last 2 Days
There are no results for your query EOLS;AGN
